Skip to content

R&D at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
$8.78M+13.3%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$5.24M+19.2%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$4.39M+34.8%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$10.6M+0.3%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$5.83M-49.1%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.88M+61.5%

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+247%
Enterprise value$1.19B+235%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's R&D?
Savara (SVRA) reported R&D of $23.4M in Q1 2026.
How has Savara's R&D changed year-over-year?
Savara's R&D increased by 22.1% year-over-year, from $19.16M to $23.4M.
What is the long-term trend for Savara's R&D?
Over 4 years (2021 to 2025), Savara's R&D has grown at a 29.4% compound annual growth rate (CAGR), from $28.99M to $81.4M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.